Most Recent
Gilbert + Tobin has recruited a leading cybersecurity lawyer from A&O Shearman, bolstering the firm’s tech and digital offering as clients faced heightened cyber risk.
Class action lawyers are expecting to see an increase in consumer and privacy cases this year, as well as a reinvigoration of shareholder litigation following a string of prominent losses, and many are counting on the High Court to clarify legal questions hanging over plaintiffs.
Construction PRO
A Hong Kong company has won its bid to claw back funds from the family of a deceased debtor who transferred a Sydney property to his wife as part of a purported separation agreement, with a court finding the transaction was intended to defraud creditors.
Prison officers in Western Australia have won an appeal over public holiday overtime in a case against the Minister of Corrective Services.
The government’s plan to hastily pass new hate speech laws alongside gun control measures is facing diverse opposition from the Coalition, religious groups and civil liberties organisations.
A constitutional challenge to the declaration of the Melbourne CBD as a ‘designated area’ has been attacked by the state government as “hypothetical”, but the case is set to move ahead despite an early end to the designation.
Pauline Hanson and Brian Burston have quietly settled a lawsuit in which Hanson alleged that Burston subjected her to victimisation in breach of the Sex Discrimination Act after she publicly accused him of sexually harassing female staff.
Marine towage giant Svitzer took adverse action against a port manager who was dismissed in the “snap decision” of an executive irritated by the manager's lack of excitement when offered a lower-paid role as part of a restructure.
Construction PRO
The government has announced new details of a $1.2 billion reserve of critical minerals required to manufacture batteries, semiconductors and military equipment, ahead of treasurer Jim Chalmers’ G7 meeting in the US this week.
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.